 Varenicline is a partial agonist of the α4β2 nicotinic acetylcholine receptor. This drugs partial agonist effect allows for the activation of this receptor at a lesser degree than nicotine while simultaneously preventing nicotine binding due to the drugs high affinity i.e.: antagonist effect for this receptor subtype. 